Metastatic Models | Oncodesign Services

Metastatic Models

Circle Oncodesign Services

Offering multiple preclinical metastatic models to fit multiple metastasis questions

For most cancer patients, a primary, solid tumor can be easily treated with surgery. Many of these patients will eventually die of cancer but as a result of refractory reoccurrence and metastasis. For this reason, metastatic models remain an essential part of the oncology toolkit.

Oncodesign Services offers a range of metastasis models that vary by injection site, which address certain parts of the complex metastatic cascade, from generation of circulating tumor cells (CTCs) to tumor growth at a distal site.

The tumor burden and dissemination of metastatic tumors can be monitored using ex vivo examination of organs or in vivo imaging such as MRI, PET, PET/MRI, SPECT and optical imaging.

Summary of available metastasic models

Metastasis Site Model Injection Site Also to Lymph Tumor type Incidence SOC
Liver CT-26 colon

LS174T colon

HCT-116 colon

CR-LRB-018P colon

MP55 melanoma

IM-PAN-010 pancreas

IV

Intrasplenic

OT

OT Caecum

OT Choroid

SC

Syngeneic

CDX

CDX

PDX

PDX

PDX

100%

60-80%

90%

100%

33%

40%

CPT-11

CPT-11

Lung 4T1 breast

Rena kidney

B16-F10 melanoma

B16-F10 melanoma

MDA-MB-231 breast

OD-BRE-0192 breast

IM-PAN-015

OT, MFP

OT

IV

Intradermal

IV

OT, MFP

SC

Yes Syngeneic

Syngeneic

Syngeneic

Syngeneic

CDX

PDX

PDX

100%

100%

100%

80-90%

66%

30%

40-60%

Doxorubicin, indomethacin

Sunitinib, Sorafenib

Cyclophosphamide

Paclitaxel

Brain B16-F10 melanoma

BT-474 breast

A-549 lung

NCI-H460 lung

CMEL-5 melanoma

Intracranial

Intracranial

Intracranial

Intracranial

IV

Yes Syngeneic

CDX

CDX

CDX

CDX

100%

100%

100%

100%

100%

Temozolomide

Paclitaxel, CDDP, TMZ, Gemcitbine

Paclitaxel

Spleen CT-26 colon caecum Syngeneic 30-40%
Bone CMEL-5 melanoma

CMEL5 melanoma

PC-3 prostate

Proprietary prostate

IV

OT

Intracardiac

Intratibial

Yes

Yes

Yes

CDX

CDX

CDX

CDX

100%

100%

69%

100%

Temozolomide

Paclitaxel

CASE STUDY #1

The B16-F10 mouse melanoma model was implanted intravenously in C57b6 mice, with lung tumor colonies measured after termination. Cyclophosphamide successfully repressed most of the lung mets forming.